Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Is Parkinson's Disease the Ideal Preclinical Population for Alzheimer's Disease Therapeutics?

Version 1 : Received: 2 July 2021 / Approved: 5 July 2021 / Online: 5 July 2021 (16:08:41 CEST)

A peer-reviewed article of this Preprint also exists.

Tropea, T.F.; Chen-Plotkin, A. Are Parkinson’s Disease Patients the Ideal Preclinical Population for Alzheimer’s Disease Therapeutics? J. Pers. Med. 2021, 11, 834. Tropea, T.F.; Chen-Plotkin, A. Are Parkinson’s Disease Patients the Ideal Preclinical Population for Alzheimer’s Disease Therapeutics? J. Pers. Med. 2021, 11, 834.

Journal reference: J. Pers. Med. 2021, 11, 834
DOI: 10.3390/jpm11090834

Abstract

Concomitant neuropathological hallmarks of Alzheimer’s Disease (AD) are common in the brains of people with Parkinson’s disease (PD). Furthermore, AD biomarkers are associated with cognitive decline and dementia in PD patients during life. Here, we highlight the considerable overlap between AD and PD, emphasizing neuropathological, biomarker, and mechanistic studies. We suggest that precision medicine approaches may successfully identify PD patients most likely to develop concomitant AD. The ability to identify PD patients at high risk for future concomitant AD in turn provides an ideal cohort for trials of AD-directed therapies in PD patients, aimed at delaying or preventing cognitive symptoms.

Keywords

Parkinson’s disease; Alzheimer’s Disease; Clinical trial; Precision medicine.

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.